Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
1.640
-0.100 (-5.75%)
At close: Jun 27, 2025, 4:00 PM
1.738
+0.098 (5.98%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Fractyl Health Revenue
Fractyl Health had revenue of $60.00K in the twelve months ending March 31, 2025, down -59.46% year-over-year. In the year 2024, Fractyl Health had annual revenue of $93.00K, down -22.50%.
Revenue (ttm)
$60.00K
Revenue Growth
-59.46%
P/S Ratio
1,338.69
Revenue / Employee
$561
Employees
107
Market Cap
80.32M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GUTS News
- 5 days ago - Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy - GlobeNewsWire
- 5 days ago - Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models - GlobeNewsWire
- 10 days ago - Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing - GlobeNewsWire
- 15 days ago - Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 24 days ago - Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide - GlobeNewsWire
- 5 weeks ago - Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes - GlobeNewsWire
- 6 weeks ago - Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 - GlobeNewsWire
- 6 weeks ago - Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases - Business Wire